ERBB2 and colorectal carcinoma: According to the maturity of clinical trials and the diversity of expression distribution in different malignancies, the surface expression of GPC3, MSLN, and HER2 on CRC cell lines was evaluated in this research, which demonstrated that HER2 is a promising target of mCRC for CAR-T therapy, consistent with the results of flow cytometry and TMA, similar to that proposed by Greally et al. [12, 13, 33].